Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP

MARAVI-PEP Trial

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP
MARAVI-PEP: Study Design

Study Design: MARAVI-PEP

- **Background**: Prospective, randomized, open-label, phase 4 trial comparing lopinavir-ritonavir versus maraviroc, both with tenofovir-emtricitabine, for HIV postexposure prophylaxis (PEP)
- **Inclusion Criteria (n=237)***
  - Age ≥18
  - Residents of Barcelona
  - Presented to ER due to potential HIV sexual exposure
  - Met criteria for PEP per Spanish guidelines
- **Treatment Arms**
  - Lopinavir-ritonavir 400-100 mg BID + TDF-FTC
  - Maraviroc 300 mg BID + TDF-FTC



*Only 187 individuals who were randomized attended first scheduled visit

Source: Leal L, et al. J Antimicrob Chemother. 2016;71:1982-6.

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP
MARAVI-PEP: Result

Day 28: PEP Non-completion



Source: Leal L, et al. J Antimicrob Chemother. 2016;71:1982-6.

National HIV Curriculum

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP
MARAVI-PEP: Result (subgroup analysis)

Day 28: PEP Non-completion (for patients attending day 1 visit – ITT)



Source: Leal L, et al. J Antimicrob Chemother. 2016;71:1982-6.

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP
MARAVI-PEP: Result

Adverse Events (reported by patients attending day 1 visit)



Source: Leal L, et al. J Antimicrob Chemother. 2016;71:1982-6.

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP
MARAVI-PEP: Result

Factors Associated with PEP Non-completion at Day 28 (univariate analysis)		
Characteristic	**PEP discontinuations due to any cause in entire cohort, OR (95% CI)** (n = 237)	**PEP discontinuations due to any cause in patients attending day 1 visit, OR (95% CI)** (n = 182)
Randomization arm: Lopinavir-RTV	1.3	2.9
Race: non-Caucasian	2.1	2.2
Risk assessment: low	1.2	4.8
Previous PEP: yes	2.4	1.6
Presence of adverse events due to PEP*	N/A	0.3

*Only measured in patients who attended day 1 visit

Source: Leal L, et al. J Antimicrob Chemother. 2016;71:1982-6.

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP
MARAVI-PEP: Conclusions

Conclusions: “PEP non-completion and adverse events were both significantly higher in patients allocated to ritonavir-boosted lopinavir. These data suggest that maraviroc is a well-tolerated antiretroviral that can be used in this setting.”

Source: Leal L, et al. J Antimicrob Chemother. 2016;71:1982-6.

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

National HIV Curriculum

AETC AIDS Education & Training Center Program
National Coordinating Resource Center